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stable coronary artery disease (CAD) patients by comparing the results to an established,
validated laboratory-based genotyping method.
Methods: 74 stable CAD patients on clop 75 mg daily were tested by clinical nurses with
no genetic laboratory experience and 1 hour of basic training on the device. The patients
were defined as EM (*1/*1, *1/*17, *17/*17), RM (*1/*2A, *1/*8, *2A/*2A, *2A/*3).
Genetic testing was conducted on 1 mL of whole blood using the Verigene® System and
compared to an Affymetrix® DMET	 assay. Pharmacokinetic (PK) exposure to clop’s
active metabolite (AM) was measured and platelet reactivity (PD) was assessed with the
VerifyNow™ P2Y12 system (PRU) and VASP (PRI) assays.
Results: There was an overall 99.9% concordance of marker-level data between the
Verigene® and the reference (DMET	) in measuring the CYP2C19 markers of interest.
There was a 100% agreement between Verigene® and the reference test in classifying the
patients into established EM and RM groups. The POC assay identified 59 EM, 15 RM.
The EM group had significantly lower PRU (LS means 158 vs. 212; p0.003), and PRI
(LS means 48 vs. 63, p0.01) than RM group treated with clopidogrel 75 mg. The EM
group also had significantly higher AM exposure by AUC(0-last) than the RM group (LS
means 12.6 vs. 7.7; p0.0009).
Conclusions: This is the first report of a POC genetic testing platform performing a
comprehensive CYP2C19 polymorphism characterization in CAD patients and validating
the genotypes against the PK and PD phenotype. There was a high concordance between
the two platforms in measuring the star allele marker data. The POC genetic test identified
EM and RM phenotypes based on 11 gene variants with high accuracy and predicted a
reduced platelet inhibition in response to clop. A rapid, reliable POC CYP2C19 genetic
test could make clop pharmacogenetic testing feasible for all patients.
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Background: There is no consensus concerning the usefulness of routine assessment of
in vitro platelet reactivity for recognition of clopidogrel nonresponders, or the method or
methods that allow reliable assessment of residual platelet reactivity, and for each method
the cutoff of platelet aggregation inhibition that should be used in clinical practice.
Methods: The study includes 1,789 acute coronary syndrome (ACS) patients receiving
an invasive treatment and for whom platelet reactivity after a 600 mg clopidogrel loading
was prospectively assessed by light transmittance aggregometry (LTA). The primary end
point of the study was a composite of cardiac death, myocardial infarction, any urgent
coronary revascularization, and stroke (MACE) at 2-year follow-up; the secondary end
point was cardiac mortality. The sensitivity and specificity of platelet reactivity to predict
both end points were calculated in a ROC curve analysis. The optimal cutoff value was
defined by the highest Youden index value and compared with the predefined cutoff of
70% used in the main study and corresponding to the 90th percentile value derived from
an healthy volunteer sample.
Results: By ROC analysis 63% resulted the optimal cutoff value to predict both MACE
and cardiac death at 2 years of follow-up. A significant sensitivity improvement for the
ROC-based cutoff value was revealed (32%; p0.001). The incidence of clopidogrel
nonresponders changed from 14% with the cutoff of 70% to 24% with the ROC-based
cutoff. However, the increased sensitivity was reached at the price of a lower specificity
and accuracy. The latter with the cutoff of 70% was 81% for MACE and 84% for cardiac
death, while with the cutoff of 63% the predictive accuracy was 73% and 75%,
respectively. The AUCs were nearly identical with the 2 cutoffs both for MACE (0.71;
95% CI 0.69-0.73) and cardiac death (0.79; 95% CI 0.77-0.81).
Conclusions: The cutoff of 70% as compared to the ROC-based of 63% allows the
identification of a subset of patients at very high risk of cardiac death in only 14% of the
studied population, making the ADP LAT test more acceptable in clinical practice for the
identification of subjects at risk.
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Background: Glycoprotein IIb/IIIa inhibitors (GPI) are widely used during percutaneous
interventions, particularly in the setting of high clot burden, slow flow, or no reflow. While
the safety of a 300 mg clopidogrel loading dose in conjunction with GPI therapy has been
established, the safety of a 600 mg clopidogrel load has not been defined.
Methods: We searched PubMed, Cochrane, and ClinicalTrials.gov for studies that
involved PCI in patients treated with a GPI plus either 300 mg or 600 mg of clopidogrel.
We excluded studies that involved oral or intracoronary GPI therapy and/or thrombolysis.
Results: Our study included 15 trials and 12,114 patients. Major bleeding incidence
ranged from 0% to 10.36% with 300 mg of clopidogrel versus 1.11% to 7.52% with 600
mg of clopidogrel. Minor bleeding incidence ranged from 0% to 25.69% with 300 mg of
clopidogrel and from 0% to 6.13% with 600 mg of clopidogrel. After excluding trials that
did not define bleeding based on TIMI criteria, the pooled incidence of major bleeding
was 1.08 (95% CI, 0.74 to 1.42)% for the 300 mg clopidogrel group and 1.46 (95% CI,
1.02-1.90)% for the 600 mg clopidogrel group (p0.91) (Figure 1A). The pooled
incidence of TIMI minor bleeding was 2.15 (95% CI, 0.44 to 3.86)% for the 300 mg group
and 3.66 (95% CI, 2.54 to 4.79)% for the 600 mg group (p0.46) (Figure 1B).
Conclusions: Among patients undergoing PCI and receiving a GPI, the incidence of
bleeding is low and similar after a 300 mg or 600 mg clopidogrel loading dose.
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Ya-Ling Han1, Quan-Yu Zhang1
1Shenyang Northern Hospital, Shenyang, Liaoning
Background: Until now there has been scarce evidence regarding an optimal antiplatelet
strategy and clinical outcomes for patients who had suffered from stent thrombosis (ST).
Methods: 140 patients who suffered from stent thrombosis were prospectively registered.
Patients received dual (aspirin and 150mg clopidogrel, N66) or triple (additional
cilostazol, N74) antiplatelet therapy at the physician’s discretion. Thereafter platelet
reactivity and one year clinical outcomes were analyzed. The primary outcome included
the composite of cardiac death, non-fatal myocardial infarction (MI) or stroke at one year.
Results: MACE developed in 41 (29.3%) patients, consisting of 31 (22.1%) cardiac
death, 9 (6.4%) non-fatal MI and 1 (1.4%) stroke. Recurrent definite and probable ST
according to ARC definition was observed in 8 (5.7%) and 14 (10.0%) patients,
respectively. Triple therapy was associated with significantly lower platelet reactivities
(50.217.8, % vs. 59.617.2, %, P0.002) compared to high dose dual antiplatelet
therapy. However, the incidence of primary events (24.3% vs. 34.8%, P0.172) did not
differ between triple and dual antiplatelet therapies. High on-treatment platelet reactivity
(HR: 8.35, 95% CI: 2.23430.867, P0.002) and diabetes (HR: 3.732, 95% CI:
1.35310.298, P0.011) were independent predictors of primary events.
Conclusions: Patients who suffered from stent thrombosis have a poor prognosis even
after revascularization with intensive antiplatelet therapy. Triple antiplatelet therapy was
more effective in reducing on-treatment platelet reactivity, compared to high dose dual
antiplatelet therapy.
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Background: The timing and incidence of adverse events by different durations of
clopidogrel therapy after SVG PCI remain unknown. The primary objective of this study
was to investigate the risk associated with cessation of long-term clopidogrel therapy after
SVG PCI.
Methods: This is a cohort study of patients undergoing SVG PCI from 2000-2009
followed for death or MI after stopping clopidogrel. A piecewise exponential survival
model was used to generate adjusted incidence rate ratios comparing the 0-90 day and
91-365 day intervals after clopidogrel cessation. A multivariate Cox regression model was
constructed to obtain risk-adjusted instantaneous incidence rates using kernel hazard
functions.
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Results: There were 603 patients who underwent saphenous vein graft PCI; 411 were
event-free at the time of clopidogrel cessation and comprised the study cohort. The
incidence rate ratio (95% CI) for death or myocardial infarction in the 0-90 day interval
compared with the 91-365 day interval was 2.58 (1.64-4.07). Similar results were
observed over a broad range of clopidogrel treatment durations (6 months, 6 months- 1
year, 1-2 years, or2 years). The results were also consistent across subgroups including
gender, stent type, stent diameter, study period, and diabetes status. The risk-adjusted
instantaneous incidence rate for death or MI was greatest early after clopidogrel cessation,
regardless of clopidogrel duration (see figure).
Conclusions: A clustering of events was observed in the initial 0-90 days after
clopidogrel cessation in all treatment durations of clopidogrel investigated after SVG PCI.
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Background: Evidence on the use of newer antiplatelet agents and their cost implications
remains scarce. Previous research has shown a shorter average hospital length of stay for
prasugrel-treated patients compared to clopidogrel-treated patients. We analyzed a large
geographically diverse database from the US and compared cost of hospitalization for
patients with acute coronary syndrome (ACS) who have undergone percutaneous
coronary intervention (PCI) and who received either clopidogrel or prasugrel.
Methods: Using a large representative US database maintained by PREMIER, we
analyzed patient characteristics and total hospitalization costs during the index (first)
hospitalization among ACS-PCI patients treated with clopidogrel or prasugrel between
July 2009 and June 2011. Analysis included patients treated with prasugrel who were
on-label and clopidogrel-treated patients who would have been eligible for prasugrel
treatment per the label. Observed costs were analyzed unadjusted and adjusted for
baseline differences using a generalized linear model with a gamma distribution and log
link function with propensity score stratification.
Results: Data were available for 75,315 patients who received clopidogrel and 9,483
patients who received prasugrel during their hospitalization. The observed mean hospi-
talization costs (SD) for clopidogrel and prasugrel, respectively, were $17,519 ($2,548)
and $17,136 ($2,562). Mean costs for clopidogrel and prasugrel recipients, respectively,
were $16,937 ($2,162) and $16,664 ($2,137) for STEMI, $17,926 ($2,747) and $17,511
($2,849) for NSTEMI, and $17,900 ($2,665) and $17,393 ($2,676) for UA (all
comparisons, P0.001). The adjusted results showed prasugrel-treated patients cost as
much as $882 less than clopidogrel-treated patients (P0.001) during the index hospital
stay.
Conclusions: Prasugrel-treated patients used fewer health care resources compared to
clopidogrel-treated patients during the index hospital stay, as measured by hospital costs.
Similar results were obtained after adjusting for patient demographics and clinical
characteristics. The potential for unmeasured confounder bias is a limitation in this
real-world observational research.
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Background: The use of any thienopyridine within 5 days before enrollment was an
exclusion criteria for the TRITON TIMI 38 Trial. There are no clinical data concerning
the safety of switching from clopidogrel to prasugrel in patients undergoing coronary
stenting. However, in the daily activity, clinicians face the decision of switching high-risk
patients from clopidogrel to prasugrel. We sought to evaluate in-hospital events in
high-risk patients undergoing coronary stent implantation and prasugrel therapy with
(SWITCH group) or without (NAÏVE group) previous clopidogrel therapy.
Methods: From March 2010 to December 2011 a total of 718 patients aged 68  11
years (32% older than 75 years) underwent stent implantation and received prasugrel
therapy (77 with a 60 mg loading dose). Of these, 370 (51%) patients have received
clopidogrel before prasugrel therapy: high residual platelet reactivity (HRPR) on clopi-
dogrel had been documented in 258 patients by LTA (ADP 10).
Results: Seventy-seven SWITCH group patients received a 60 mg prasugrel loading
dose. NAÏVE group patients were more likely to have ST-elevation myocardial infarction
(60% vs 15%) and a younger age (mean age 66 vs 70 years). There was no difference in
BARC in-hospital bleeding (4.1% vs 4.9%; p0.578) between the SWITCH and NAÏVE
groups as well as in mortality, acute stent thrombosis, reinfarction and stroke rates. At
multivariable analysis, independent predictors of in-hospital bleeding were female gender
(OR 3.53 [1.34-9.35], p0.011) and diabetes (OR 3.22 [1.23-8.37], p0.017), but
switching therapy did not. This result was confirmed after switching propensity score
adjustment (c-statistic 0.77; Hosmer-Lemeshow test p 860). In patients with HRPR on
clopidogrel, prasugrel decreased platelet aggregation from 7211% to 4316%
(p0.001).
Conclusions: Switching from clopidogrel to prasugrel in high-risk patients undergoing
coronary stent implantation seems to be not associated with any short term major concerns
regarding prasugrel safety and efficacy.
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Background: Paraoxonase (PON) is a high-density-lipoprotein (HDL) associated en-
zyme with antioxidative and anti-atherogenic property. Its function is associated with
coronary artery disease and its activity genetically controlled. We evaluated whether
genetic variation of PON-1 is associated with clinical outcome in a large cohort of Korean
patients with drug-eluting stents implantation.
Methods: A total of 1676 patients with drug-eluting stent implantation were enrolled in
the prospective CROSS-VERIFY cohort from June 2006 to June 2010. We genotyped the
PON1-Q192R gene, measured clopidogrel on-treatment platelet reactivity (OPR), and
analyzed lipid profiles. The primary endpoint was the composite of cardiac death,
myocardial infarction, and stent thrombosis at 12 months.
Results: PON-1 genotyping data were available in 1336 patients. Since the Q-allele is
associated with decreased PON-activity, we analyzed the outcome between patients with
QQ/QR (815 patients, 61%) and those with RR-genotype (521 patients, 39%). After
adjustment for common cardiac risk factors, the QQ/QR-genotype was an independent
predictor of the primary thrombotic endpoint with an 11-fold increased risk (HR 11.5,
95% CI: 1.54-86.6), but not repeat revascularization (HR 1.13, 95% CI: 0.78-1.62). The
QQ/QR-genotype was not associated with OPR (QQ/QR: 23186 PRU vs. RR 23682
PRU, p0.342) but higher small-dense LDL levels (1.200.12 mg/dL vs. 0.760.15
mg/dL, p0.027). The increased risk of thrombotic outcomes was more profound in acute
coronary syndrome (ACS) patients compared with non-ACS patients.
Conclusions: PON1 Q-allele is an independent predictor of worse cardiovascular
outcome independent of platelet function and is associated with significantly higher levels
of small dense LDL-C. PON-1 genotype may serve as a novel genetic risk factor for
adverse events after PCI.
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